Abstract | PURPOSE: METHODS: Sixty-eight AAU HLA-B27+ patients were randomly selected for treatment with prednisolone acetate 1% or Rimexolone 1%. All patients showed mild to moderate anterior chamber inflammation. This was a prospective, randomized, double blind, clinical trial. RESULTS: There was no statistically significant difference between both groups when anterior chamber cells were measured. In the rimexolonae group, flare diminished since the first week. In both groups the intraocular pressure (IOP) raised since the first week, the increase was highly significant in the rimexolone group. Final intraocular pressure was higher in the prednisolone group. CONCLUSION:
Rimexolone 1% is as effective as prednisolone acetate 1% in the treatment of mild to moderate AAU HLA-B27+. IOP increased in both groups, but this variation was not clinically significant.
|
Authors | Lourdes Arellanes-García, Gonzalo Padilla-Aguilar, Patricia Navarro-López, Cynthia Espinoza-Martínez |
Journal | Gaceta medica de Mexico
(Gac Med Mex)
2005 Sep-Oct
Vol. 141
Issue 5
Pg. 363-6
ISSN: 0016-3813 [Print] Mexico |
Vernacular Title | Comparación de la eficacia de la prednisolona y la rimexolona en el tratamiento de iridociclitis aguda en pacientes HLA-B27 positivos. |
PMID | 16353881
(Publication Type: Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Inflammatory Agents
- HLA-B27 Antigen
- Pregnadienes
- Prednisolone
- rimexolone
|
Topics |
- Acute Disease
- Adult
- Anti-Inflammatory Agents
(therapeutic use)
- Double-Blind Method
- Female
- HLA-B27 Antigen
(blood)
- Humans
- Longitudinal Studies
- Male
- Prednisolone
(therapeutic use)
- Pregnadienes
(therapeutic use)
- Prospective Studies
- Uveitis
(blood, drug therapy)
|